BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23386643)

  • 1. Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.
    Wang Y; Radhakrishnan D; He X; Peehl DM; Eng C
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E586-94. PubMed ID: 23386643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas.
    Wang Y; He X; Yu Q; Eng C
    Hum Mol Genet; 2013 Jun; 22(11):2263-72. PubMed ID: 23418309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma.
    Wang Y; Roma A; Nolley R; Abdul-Karim F; Peehl DM; Eng C
    Endocr Relat Cancer; 2014 Aug; 21(4):579-86. PubMed ID: 24972837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers.
    Wang Y; Romigh T; He X; Tan MH; Orloff MS; Silverman RH; Heston WD; Eng C
    Oncogene; 2011 Oct; 30(42):4327-38. PubMed ID: 21532617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation.
    Wang Y; Yu Q; He X; Romigh T; Altemus J; Eng C
    Mol Cancer Ther; 2014 Feb; 13(2):517-27. PubMed ID: 24356815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.
    Augello MA; Liu D; Deonarine LD; Robinson BD; Huang D; Stelloo S; Blattner M; Doane AS; Wong EWP; Chen Y; Rubin MA; Beltran H; Elemento O; Bergman AM; Zwart W; Sboner A; Dephoure N; Barbieri CE
    Cancer Cell; 2019 Apr; 35(4):603-617.e8. PubMed ID: 30930119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress.
    Lehman JA; Waning DL; Batuello CN; Cipriano R; Kadakia MP; Mayo LD
    J Biol Chem; 2011 Oct; 286(42):36631-40. PubMed ID: 21873427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tumor suppressor dysregulation in prostate cancer progression.
    Dean JL; Knudsen KE
    Curr Drug Targets; 2013 Apr; 14(4):460-71. PubMed ID: 23410128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
    Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
    Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model.
    Abou-Kheir WG; Hynes PG; Martin PL; Pierce R; Kelly K
    Stem Cells; 2010 Dec; 28(12):2129-40. PubMed ID: 20936707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
    Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
    Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
    Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
    Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ING3 promotes prostate cancer growth by activating the androgen receptor.
    Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
    BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of the tumor suppressor, Tp53, enhances the androgen receptor-mediated oncogenic transformation and tumor development in the mouse prostate.
    He Y; Johnson DT; Yang JS; Wu H; You S; Yoon J; Lee DH; Kim WK; Aldahl J; Le V; Hooker E; Yu EJ; Geradts J; Cardiff RD; Sun Z
    Oncogene; 2019 Sep; 38(38):6507-6520. PubMed ID: 31358900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.
    Li P; Lee H; Guo S; Unterman TG; Jenster G; Bai W
    Mol Cell Biol; 2003 Jan; 23(1):104-18. PubMed ID: 12482965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.